Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can someone explain what #7 in the proxy is about?
7.
Special resolution to authorize and approve that, subject to the confirmation of the High Court of Justice in England and Wales, the amount standing to the credit of the share premium account of the Company as at the date of the court hearing be cancelled (the "Reduction of Capital").
Board Recommendation:
For
For
Against
Abstain
Thanks Kiwi for that information. If I had speculate on some of that, I would say this: When comparing Fosrenol powder and tablets, the powder would possibly be better or more fully absorbed hence more negative reactions for the powder.
As far as comparing OLC and fosrenol tabs, there really shouldn't be much of a difference in side effects but it is always possible that in the studies with fosrenol tablets, there were compliance issues, which means that more of the subjects did not get the full dose of fosrenol and hence less side effects.
So no increase in power if still sticking with 60 to crunch data with.
When my kid was about 10 or 11 I had a custodial account for him. He wanted to buy Apple and I told him that the analysts were all down on it, with no confidence that it would be a going concern going forward. We didn't buy and we all know the rest of the story.
Kiwi, RZLT not giving me a break to buy in as it keeps marching north. I do have to tell you about a drug approval that I did handle correctly (of course you remember Amarin's label expansion). I was in EYEN and they received approval of their drug candidate Monday night. The stock was not behaving as it should have that day and when the approval came in the after market, it did not move at all. I dumped in the after hours market immediately when I saw that. I had intentions of selling on the pop, but there was no pop and the following days it has dropped. Of course it did have a rise during the month prior. Glad to get out.
Sad to hear Nuke. I won’t recount my horror stories. The opportunity costs of holding Amarin have been incalculable.
Thanks for the heads up Kiwi. That is good news on the trial considering they expanded it by 50%.
With ya.
I was lying in bed this morning and a thought came to mind. There used to be a time where advertising for drugs was not permitted. I suppose drug reps back then were still allowed to visit and promote drugs to the doc. And, it seems to be clear that with advertising and promotion sales of drugs (I am clearly thinking Vascepa foremost although it is for every drug) that sales dwarf any sales without advertising. But, it makes me wonder what are the docs doing? I mean, isn't it supposed to be their job to find the best treatment for their patients, regardless as to whether someone is advertising it. Lest it be said that "how is the doc supposed to know", drugs are typically included in health organizations recommendations (as Vascepa is in a number of them), and, of course, study results are published in prestigious journals. One would think that a doc doing his job trying to do best by his patient should easily be aware of drugs, like Vascepa, without the need for advertising. Now, the only thing missing without advertising would be patients who, after seeing commercials, would theoretically pester their doc for a drug. It is, for me anyway, a sad commentary that the uptake for V is so slow even without ads or salespeople, especially considering that there are Generics for it available! So it is not like prescribing the drug involves some Uber-expensive treatment.
I think it is normal that we now point to the April 2 appeal, but reading through the CC transcript I see no mention of it, either by Holt, etc., or even a question about it from any of the analysts. I guess no one really that interested or don't have much hope for it. I don't mind the company not raising any expectations though. I was invested in Elan a long time ago and it raised itself from the dead about three times, so hopefully something develops here.
This appeal would be a good place for it to happen.
We have to remember though, that most if not all diet induced weight loss has the same negative effects in terms of loss of muscle mass, etc.
Thanks for going North. I assume (you know they say about that) that just like when you and Marjac argued, that we should be able to get live audio?
Not sure which one you are referring to but the one at the appeal court against Hikma is in April
Well, no one can say that we haven't had a plethora of chances to buy this on the cheap. The question going forward is whether we will have an opportunity to unload at a decently higher price. I know that some long timers, like MrMain, Invest, Louie, myself and others would be happy to get out with our skins intact at almost anything between $5 and $10. With all the extra shares picked up cheaply over the last few years, that $10 would yield for us much more than just our skins. Capital Gains big time! LOL
There has to be some news that we are not privy to. Huge beat down
Thanks.
Robin on ST claiming that someone reduced their price target to $1.08 as the cause of this. Can anyone verify or what analyst she/he is talking about?
What, all over preannounced earnings?
Saw your post about this on another board. I am pi$$ed a bit because I had been trying to buy this from about a couple of weeks ago, but it kept running away from me. I was attempting to liquidate something and pick this up and it became a frustrating experience. Maybe I may have a chance if it retraces a bit?
I can live with a one quarter push back in terms of trial results. UNCY yesterday reversed the week long slide (the slide was actually constructive since it had gotten overbought) and hopefully Monday continues the upward trend.
On that occasion the heart valve/bypass operation for my mom ended well. Although she also had angioedema where they kept her intubated for a week in ICU and it was a bit of a scary moment when a large group of docs and nurses assembled around her to remove the tube. They said they were worried that her airway could collapse and were at the ready to perform a tracheotomy. Luckily that was not necessary. She went on to live another 12 years after that surgery, although the last few years were not that great and I might not be interested in hanging on through that. Thanks for asking.
I would use a different word than "slow". Since the time the other day when it was not working at all, it has been terrible. Interestingly, I find that the app on my phone seems to work fine.
Kiwi, I agree that they will need more funds. Question is, will the raise be before or after Q2 trial results?
Couple of other items. On another board you were questioning Cervelo about his kidneys and mentioning you had a friend whose kidneys shut down after some procedure. It reminded me of when my mom had a heart valve replacement (and a couple of arteries bypassed at the same time). The doc came out to talk to me after the procedure to tell me that all went well but that since they had to stop my mom's heart and put her on a machine, that the kidneys stopped functioning and that they were monitoring them for when they returned to full function. He seemed to indicate that it was normal in that type of surgery.
Also I suddenly was wondering if calling you Kiwi all these years was derogatory, so I googled it. Most search results indicated that it was not considered derogatory but there were one or two that did. Hopefully it is not as you know I do not wish that.
For sure KNJS. I did take some profits after R-I readout, but lay the fault on myself for not selling all that night of label expansion. Approval is one thing, but ultimately company has to deliver on the launch and in most cases the stock price drifts down after approval for the vast majority of drug approvals. But, that is different from the $1 level. All this was caused by something that happened on and before March 31, 2020. We had drifted into the low teens and if not for what happened on March 31, ultimately the stock price would have risen with rising scripts. So we would have seen 20 again easily. Those that drove the price down to 13 before the verdict were smart (unlike management who did not protect their only drug and unlike me). I want to kick my ass everyday that I wake up.
At first, considering label expansion in late December 2019, the Total OpEx of over 500m could be understood as the CVD indication being rolled out. But, really, the DuDisaster happened on March 31, and although Generics didn't enter the market at that point (only months later) it is clear that JT and the gang did not act as they should have wrt conserving cash. Still remember how shellshocked JT sounded the day after. Heck even 2021 had a huge OpEx when Generics had well entered the game.
Thanks for your graphs.
What I have a hard time to understand is the thought process of those selling. I mean what were they expecting from the ER? The situation is pretty clear and transparent. Any new or big developments that could have affected the ER would have been out there.
I believe Charlie Munger once said: “The big money is not in the buying or selling, but in the waiting.”
And then there is the other saying that the stock market is a mechanism for transferring wealth from the impatient to the patient.
Of course on the other hand, being one of the long time sufferers here, I can sympathize and concur with some of those feelings of frustration.
I don’t think Buffet and Munger really thought of timelines like more than 12 years when they referred to patience. Of course we have no choice so I have acquired the ability to be patient.
Well Invest, if we weren't insane when we first invested here, we definitely are insane by now.
Marjac indicated that that scenario increased the likelihood of some type of settlement though.
Cosa, you pose an excellent question and it is surprising that it hasn’t received more attention and discussion here. There are obviously cases where a share buyback makes sense, but not usually when you are a small company attempting to launch and grow a drug - your only drug.
I have to assume that these initiatives have some end goal which was not divulged to us but possibly became clear to management thru the SR.
Congrats on VKTX. I made some coin a year ago there but never got back in.
Agree with your thinking. If results of trial are good, any capital raise won't matter. I just added more.
Yes, good to see you haven’t left us LB. Remember all the discussion of a beach house. Thanks Invest for remembering me in our forlorn group.
This is old but a good reminder of what we have here:
https://karger.com/ajn/article/54/5-6/219/843793/High-Phosphate-Binding-Capacity-of-Oxylanthanum
Also wondering if UNCY was requested by the FDA or thought it better to increase trial size by 50%?
Thanks, that is good stuff! Hopefully another piece to help with the EU. Until Generics are run out of town, not much help for the US.
For sure Zip, especially since this case (infringement) is not the same as what Marjac and North were working on and got shut down on standing.
The only thing that I find as a negative is the flip of the coin as to who we get. What I mean by that, is of the 12 judges (I just checked and saw that there are 12 listed but I could have sworn that there were only 9 at the time of Marjac's case) Newman is out and then we have to hope not to get those other same 2, Dyk and whoever. So I guess 9/12 still leaves a good chance but I still fret about getting Dyk and the other guy.
Thanks Capt for the additional info about the dismissal. Hopefully, any potential settlement doesn't simply involve both parties dropping their respective suits against one another. They are not equal.
Thanks DMC8.
Do we know who will be doing the arguing that day for Amarin?
Not only that, but also: "Aurinia also explored potentially acquiring or licensing other entities or assets during this time." So they did a lot of stuff in 7 months. Of course JP Morgan was doing most of that I guess.
All of which led to this: "The Board ultimately determined that none of the explored opportunities that were available to it to pursue were in the best near-term interests of the Company to execute on, and that the best path forward is for management to streamline its operations as it announced today and focus on the Company’s commercial execution."
We will now have to see what their focus on commercial execution brings as far as any changes to the plan and the results.
Well according to the ER, they were to commence “on or about Feb, 21”, so it could be. Still curious as to a small co GIA repurchasing shares.